Alzheimer's Research Studies in Las Vegas

02What biomarker research actually studies

Biomarker research is narrower than most people expect from the word research, and understanding the difference makes participation easier to evaluate.

Biomarkers, in plain terms

A biomarker is a measurable biological signal that indicates something about a disease: whether it is present, how far it has progressed, or how it is likely to behave. In Alzheimer's disease the relevant signals include changes measurable in blood and on imaging, and the research question is how reliably those signals identify the disease process, particularly earlier than symptoms allow. The National Institute on Aging maintains public material on where this field currently stands.

How it differs from a treatment trial

A treatment trial asks whether an intervention helps. Biomarker research usually asks whether a measurement means what it is thought to mean. The distinction matters to a participant because the two involve different commitments and different expectations: a biomarker study typically involves assessments and samples rather than taking an investigational drug, and its benefit is to knowledge rather than to the individual participant. The Alzheimer's Association publishes accessible material on the kinds of studies available and what each involves.

Why earlier identification is the point

Memory evaluation currently separates normal ageing from treatable contributors, then mild cognitive impairment from dementia, largely on clinical grounds supported by imaging and laboratory work. Those are four different conversations, described on the memory and dementia page. A reliable biomarker would sharpen that separation and move it earlier, which is where the practical value lies, because a distinction drawn earlier gives families more time to plan and clinicians more options to consider.

03Alzheimer's research study Southern Nevada: who can take part

Eligibility is set by each study protocol rather than by the practice, and that is worth stating plainly because it explains why the answer to "can I join" is often "it depends on which study is open".

What informed consent actually involves

Informed consent is a process rather than a signature. It means the purpose of the study, what will happen at each visit, how long it runs, what is being measured, what the known risks are, what happens to your samples and data, and what you may decide later are all explained before anything study-related begins. Questions are expected at that point and later, and taking a document home to read or discuss with family is normal rather than obstructive. A site that treats consent as paperwork to be completed quickly is not running the process properly.

Privacy, samples and what happens to your data

Study data is handled under the protocol rather than under ordinary clinical rules, and the two are not identical. What is collected, how it is identified or de-identified, who may access it, how long it is retained and whether samples may be used in future related research are all specified in advance and covered during consent. Where a study proposes future use of samples, that is a separate question you can agree to or decline independently of joining the study itself.

Family members and study partners

Memory research frequently involves a study partner, meaning someone who knows the participant well and can describe changes from an outside perspective. That reflects a clinical reality rather than a research quirk: in memory conditions the person best placed to notice change is often not the patient. Where a study requires a partner, both people are told what the commitment involves before either agrees.

What a screening conversation covers

Screening is where most questions get answered, and it happens before consent rather than after. It establishes whether the protocol's criteria are met, explains what the visit schedule looks like in practice, and gives you the chance to ask what the study is actually measuring and why. People sometimes expect screening to be a formality; it is closer to a two-way assessment, and declining at that point is common and entirely expected.

Cost, and what participants are and are not asked for

Study visits conducted under a protocol are not billed to a participant. What participation does cost is time, and being straightforward about that is more useful than emphasising the absence of a fee. Visit schedules vary by study and are set out during screening, before consent, so a decision can be made against the actual commitment rather than an estimate.

04Alzheimer's research study Henderson NV and across the valley

Participants are seen at the same two offices as clinical patients, and the choice between them is a travel decision. Research visits are often longer than a routine appointment and sometimes more frequent, which makes the commute a more significant factor here than elsewhere on this site.

Alzheimer's research study Henderson NV and Green Valley

The West Horizon Ridge Parkway office sits just off the 215 Beltway and generally suits Green Valley, Anthem and the southeast valley. Patients looking for an Alzheimer's research study Green Valley Henderson residents can reach without a long drive should ask about this address specifically.

Alzheimer's research study Summerlin and the west valley

The West Flamingo Road office is usually the shorter trip from Summerlin, Spring Valley and Enterprise, with the 215 and Summerlin Parkway feeding toward it. An Alzheimer's research study Summerlin residents enquire about will normally be run from there.

Alzheimer's research study North Las Vegas and the northwest

CNS consolidated from a wider footprint into two offices, so people seeking an Alzheimer's research study North Las Vegas residents can attend travel to whichever address is closer. We will not imply a third site exists.

Alzheimer's research study Southern Nevada participation, and why local sites matter

An Alzheimer's research study Southern Nevada residents can join locally is worth more than the same study three states away, and not only for convenience. Research findings generalise best to populations resembling the people studied, and a region under-represented in trials ends up relying on evidence gathered elsewhere. Southern Nevada is demographically distinct enough that this matters: the age profile, the proportion of retirees who relocated here, and the Spanish-speaking share of the population all differ from the national averages that most historical cohorts reflect.

The practical consequence for a participant is straightforward. Taking part where you already receive care means the practice holding your record is the practice conducting the assessments, so a change noticed clinically and a change measured under a protocol are visible to the same team. That is a genuine advantage of a practice-based site over a standalone research centre, and it is the main reason CNS took the partnership on rather than referring people out.

How to ask about what is currently open

Study availability changes, which is why this page describes the partnership and the process rather than listing open studies with enrolment numbers that would be out of date within weeks. To ask what is currently recruiting, contact the practice and say that research is what you are asking about, so the enquiry reaches the right person rather than the general scheduling queue. Guidance on preparing for a first visit is on the new patient page.

05What this page deliberately does not claim

Research pages attract overstatement more than any other kind of medical page, because the subject matter is genuinely hopeful and hope is easy to oversell. Four things are therefore absent here on purpose.

One more absence worth naming: there is no attempt here to persuade anyone to participate. A research page that reads as recruitment copy undermines the consent process it precedes, because a decision made under persuasion is a weaker decision even when it is the same decision. What this page tries to do instead is describe the commitment accurately enough that a reader can decide for themselves whether to ask a further question.

There are no enrolment figures, completion rates or results. Those change, and a number published once and left to age misleads more effectively than no number at all. Where you want current detail, ask the practice.

There is no promise of benefit to a participant. Research exists because the answer is not yet known, and a site implying that taking part will help you specifically has misdescribed what a study is. Some participants gain access to assessments they would not otherwise have; that is a genuine consequence and it is not a treatment benefit.

There is no suggestion that participation is a route to faster or better clinical care. It is not, by design, and the separation between research and care runs in both directions.

And there is no claim of a breakthrough, a solved disease or a discovery attributable to this site. What CNS can accurately say is that it is a participating site in biomarker research through the Global Alzheimer's Platform Foundation partnership, that the partnership was announced in September 2025, and that adults in Southern Nevada can take part locally. Everything beyond that belongs to the researchers publishing the findings, and the conditions hub is the better starting point for anyone whose question is clinical rather than research-related.